Metformina Dinerfene Laboratórios Azevedos - Indústria Farmacêutica

Active Ingredient:: Metformin Hydrochloride
Origin:: EU

Metformina Dinerfene Laboratórios Azevedos - Indústria Farmacêutica (Metformin Hydrochloride)

Q: What is Metformina Dinerfene used for?

Metformina Dinerfene contains metformin hydrochloride, which is prescribed to improve blood glucose control in adults with type 2 diabetes, to delay progression in prediabetes, and to help manage gestational diabetes when diet alone does not achieve target levels.

Q: How does Metformin Hydrochloride work?

Metformin works by suppressing hepatic glucose production, increasing insulin‑mediated glucose uptake in muscle and fat, and modestly reducing intestinal glucose absorption. These actions are mediated through activation of AMP‑activated protein kinase, improving overall insulin sensitivity without stimulating insulin release.

Q: What is the usual dose of Metformina Dinerfene?

The appropriate dose of Metformina Dinerfene is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Q: Is Metformina Dinerfene safe during pregnancy or breastfeeding?

Safety data for metformin in pregnancy and lactation are limited. It may be used during pregnancy when the benefits outweigh potential risks, but the decision must be made by a qualified clinician. Breastfeeding mothers should discuss potential exposure with their healthcare provider.

Q: How do I order Metformina Dinerfene from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does Metformina Dinerfene compare with other antidiabetic drugs?

Metformina Dinerfene belongs to the biguanide class and is generally weight‑neutral, unlike some sulfonylureas that can cause weight gain. It does not cause hypoglycemia when used alone, unlike insulin or meglitinides, and has a well‑established cardiovascular safety profile.

Q: How should Metformina Dinerfene be stored and handled?

Store Metformina Dinerfene at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the container tightly closed and out of reach of children. Do not use if the tablet shows signs of damage or discoloration.

Q: How is Metformina Dinerfene administered?

Metformina Dinerfene is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a glass of water. The exact timing and frequency are set by the prescribing clinician based on therapeutic goals.

Q: What are the most serious risks to watch for while taking Metformina Dinerfene?

The most serious adverse events include lactic acidosis, which is rare but life‑threatening, and severe skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience unexplained muscle pain, rapid breathing, abdominal discomfort, or skin blistering.

Q: Who should not use Metformina Dinerfene?

Metformina Dinerfene is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, or those receiving radiographic contrast studies that may affect kidney function.

Metformin Hydrochloride, the active ingredient in Metformina Dinerfene, is a biguanide presented as an oral tablet for oral use. It lowers blood glucose levels and is indicated for the management of type 2 diabetes mellitus and related glucose‑handling disorders. It improves peripheral insulin sensitivity and reduces hepatic glucose output, helping achieve glycemic control.

GNH India supplies Metformina Dinerfene as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution.

Manufacturer / TM Owner

Laboratórios Azevedos - Indústria Farmacêutica, S.A.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Metformina Dinerfene (metformin hydrochloride) is used to improve glycemic control in several glucose‑regulation disorders.

Type 2 diabetes mellitus: reduces fasting and post‑prandial blood glucose levels.
Prediabetes (impaired glucose tolerance): delays progression to overt diabetes.
Gestational diabetes mellitus: assists in controlling maternal blood glucose when diet alone is insufficient.

How It Works

Metformin hydrochloride acts primarily by inhibiting hepatic gluconeogenesis, thereby decreasing endogenous glucose production. It also enhances peripheral glucose uptake by increasing insulin‑mediated translocation of GLUT‑4 transporters in muscle and adipose tissue, and modestly reduces intestinal glucose absorption. The drug does not bind to a specific receptor but influences cellular energy status through activation of AMP‑activated protein kinase (AMPK), which contributes to its metabolic effects.

Side Effects

Metformina Dinerfene may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

Nausea: mild to moderate stomach upset.
Diarrhea: loose stools, often transient.
Abdominal discomfort: cramping or pain.
Metallic taste: transient alteration in taste perception.
Loss of appetite: reduced desire to eat.
Vomiting: occasional emesis.

Serious or Rare Side Effects

Lactic acidosis: life‑threatening accumulation of lactate.
Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
Hepatic dysfunction: elevated liver enzymes or hepatitis.
Hypoglycemia: especially when combined with insulin or sulfonylureas.
Vitamin B12 deficiency: anemia and neuropathy with long‑term use.

Precautions & Warnings

Before initiating Metformina Dinerfene, several safety considerations should be reviewed.

Renal function assessment: evaluate eGFR and avoid use if severe renal impairment.
Hepatic function monitoring: check liver enzymes periodically.
Contraindication in severe renal disease: do not prescribe if eGFR <30 mL/min/1.73 m².
Use with caution in elderly: increased risk of lactic acidosis.
Monitor vitamin B12 levels: long‑term therapy may cause deficiency.
Store at below 25°C: keep in the original packaging, protect from moisture and heat.

Avoid Interactions

Metformina Dinerfene can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk.
Cimetidine: can raise metformin plasma concentrations.
Alcohol excess: enhances risk of lactic acidosis.
Renal‑impairing drugs (e.g., NSAIDs, ACE inhibitors): may reduce metformin clearance.

Moderate Interactions (Monitor Closely)

Beta‑blockers: may mask hypoglycemia symptoms.
Sulfonylureas or insulin: increase risk of hypoglycemia.
Diuretics (thiazides): may affect glucose control.
Warfarin: may require INR monitoring.
Thyroid hormones: may alter glycemic response.

Frequently Asked Questions

Metformina Dinerfene contains metformin hydrochloride, which is prescribed to improve blood glucose control in adults with type 2 diabetes, to delay progression in prediabetes, and to help manage gestational diabetes when diet alone does not achieve target levels.

Metformin works by suppressing hepatic glucose production, increasing insulin‑mediated glucose uptake in muscle and fat, and modestly reducing intestinal glucose absorption. These actions are mediated through activation of AMP‑activated protein kinase, improving overall insulin sensitivity without stimulating insulin release.

The appropriate dose of Metformina Dinerfene is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for metformin in pregnancy and lactation are limited. It may be used during pregnancy when the benefits outweigh potential risks, but the decision must be made by a qualified clinician. Breastfeeding mothers should discuss potential exposure with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformina Dinerfene belongs to the biguanide class and is generally weight‑neutral, unlike some sulfonylureas that can cause weight gain. It does not cause hypoglycemia when used alone, unlike insulin or meglitinides, and has a well‑established cardiovascular safety profile.

Store Metformina Dinerfene at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Keep the container tightly closed and out of reach of children. Do not use if the tablet shows signs of damage or discoloration.

Metformina Dinerfene is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a glass of water. The exact timing and frequency are set by the prescribing clinician based on therapeutic goals.

The most serious adverse events include lactic acidosis, which is rare but life‑threatening, and severe skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience unexplained muscle pain, rapid breathing, abdominal discomfort, or skin blistering.

Metformina Dinerfene is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, or those receiving radiographic contrast studies that may affect kidney function.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 06 Sep 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.